Clinical trial
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride)…
NCT00283959 · Amicus Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00283959 |
|---|---|
| Title | A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease |
| Official title | A Phase 2, Open-Label, Single Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients With Fabry Disease |
| Lead sponsor | Amicus Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | migalastat HCl |
| Enrollment | 4 |
| Start date | Jun 27, 2006 |
| Primary completion | May 8, 2008 |
| Completion | May 8, 2008 |
| First posted | Jan 31, 2006 |
| Last update posted | Oct 31, 2018 |
| Countries | Australia, Brazil |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: